// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























30348 Abstracts

Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases.

Vasiliki Michalarea - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).

Mitsukuni Suenaga - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Novel mutations in sporadic typical carcinoids of the lung (lung-TC): Tumor genomic profile by next generation sequencing (NGS).

Ivana GABRIELA Sullivan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial.

Marta Schirripa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.

Roel Gopez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

Alessandra Fabi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab emtansine

Predictive role of clinical benefit (CB) at 1st line on the outcome of subsequent lines in metastatic breast cancer (MBC) patients: analysis of a real life population.

Ornella Garrone - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

BONADIUV trial: A single blind, randomized placebo controlled phase II study using oral ibandronate for osteopenic women receiving adjuvant aromatase inhibitors: Final safety analysis.

Lorenzo Livi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ibandronic acid

Prognostic and predictive role of tumor-infiltrating lymphocytes in luminal b subtype breast cancer treated with neoadjuvant chemotherapy: A retrospective mono-institutional case series.

Matteo Duca - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacyAn Italian multicenter experience.

Stefania Eufemia Lutrino - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Eribulin

Image-based collection to allow isolation and analysis of pure intact tumor cell populations from FFPE: Implications for more precise HER2 FISH analysis.

Amanda Gerber - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer.

Claudia Omarini - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

taxane

Single-cell sorting and recovery of pure tumor cell populations to enable molecular sequence analysis of tumor tissue specimens limited by size and or tumor content.

Valeria Sero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copy number analysis by high resolution cytogenetic analysis affymetrix oncoscan FFPE array of intraductal papillary neoplasms of the pancreas.

Silvia Vecchiarelli - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Intraductal papillary mucinous neoplasm

N/A

Mediterranean Diet influences breast cancer relapse: preliminary results of the SETA PROJECT.

Claudia Biasini - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Lutein

Factors modulating worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in postmenopausal hormone users.

Gabriella Rondanina - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Tamoxifen

Italian perspective bone metastases (BM) database: The first one-year experience.

Alberto Bongiovanni - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

N/A

Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): A metanalysis of randomized clinical trials (RCTs).

Giuseppe Lombardi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment.

Christian Diego Rolfo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

ARGX-111

Early neutrophil to lymphocyte ratio dynamics to predict progression free survival in patients treated with immune-checkpoint inhibitors.

Michele Moschetta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved